Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(1)
1 unique interventions1 categories

Analytics

Trial Phases

Phase 21

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT03213665Phase 2Completed
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
PrincipalinvestigatorStart date: 2017-11-13

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

David Maloney

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Recurrent Non-Hodgkin LymphomaRefractory Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Brenda Sandmaier

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Related
12 trials

Shared therapeutic areas:

Recurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Alex F Herrera

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Ajay Gopal

Fred Hutch/University of Washington Cancer Consortium

Related
8 trials

Shared therapeutic areas:

Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

David Hui, MD

M.D. Anderson Cancer Center

Related
13 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Giselle Sholler, MD

Beat Childhood Cancer at Atrium Health

Related
10 trials

Shared therapeutic areas:

Refractory NeuroblastomaWilms Tumor
Similarity Score1%

Anthony El-Khoueiry, MD

University of Southern California

Related
6 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

A P Chen

National Cancer Institute LAO

Related
8 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Sriram Yennu

M.D. Anderson Cancer Center

Related
12 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Brenda Sandmaier

Fred Hutch/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Refractory Hodgkin LymphomaRecurrent Hodgkin Lymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score1%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT03213665Phase 2PrincipalInvestigator

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin Lymphoma+38 more
Completed

All 1 trials loaded